A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
出版年份 2012 全文链接
标题
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 107, Issue 2, Pages 280-286
出版商
Springer Nature
发表日期
2012-06-15
DOI
10.1038/bjc.2012.257
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours
- (2012) A. Frost et al. Current Oncology
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Effect of ON 01910.Na, an Anticancer Mitotic Inhibitor, on Cell-Cycle Progression Correlates with RanGAP1 Hyperphosphorylation
- (2011) I. A. Oussenko et al. CANCER RESEARCH
- Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
- (2011) D. Olmos et al. CLINICAL CANCER RESEARCH
- A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
- (2011) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Association Between Vitamin D and Risk of Colorectal Cancer: A Systematic Review of Prospective Studies
- (2011) Yanlei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Mitosis is not a key target of microtubule agents in patient tumors
- (2011) Edina Komlodi-Pasztor et al. Nature Reviews Clinical Oncology
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) S. Cascinu et al. ANNALS OF ONCOLOGY
- Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536
- (2010) K. V. Gleixner et al. CANCER RESEARCH
- An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
- (2010) R.-D. Hofheinz et al. CLINICAL CANCER RESEARCH
- Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
- (2010) Klaus Strebhardt NATURE REVIEWS DRUG DISCOVERY
- Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
- (2009) P. Schoffski ONCOLOGIST
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
- (2008) Volker Heinemann et al. BMC CANCER
- Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
- (2008) Klaus Mross et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started